EGFR-targeting antitumor therapy: Neuregulins or antibodies?

Malignancies such as lung, breast and pancreatic carcinomas are associated with increased expression of the epidermal growth factor receptor, EGFR, its role in pathogenesis progression tumors has made this receptor a prime target development antitumor therapies. In therapies targeting resistance owing to mutations single nucleotide polymorphisms, ligands themselves very serious issues. work, both ligand neuregulin bispecific antibody fragment EGFR conjugated separately or together same drug-delivery system find most promising candidate. Camptothecin is used model chemotherapeutic drug superparamagnetic iron oxide nanoparticles delivery system. Results show that lowest LD50 achieved by formulations ligand, demonstrating synergy. Additionally, location nucleus favors activity Camptothecin. The high loading capacity efficiency convert these systems into good alternative for administering Camptothecin, whose use otherwise severely limited chemical instability poor solubility. Our choice agents allows treating express ErbB2 (Her2+ tumors) well Her2- expressing EGFR.